Tenmile

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapeutics. The company specializes in alpha-emitting isotopes that are linked to molecules designed to deliver targeted cytotoxic radiation directly to tumors. This approach allows for radiotherapy at the molecular level, addressing significant challenges in targeted alpha therapy, particularly in ensuring a reliable and scalable supply. AdvanCell aims to provide safe and effective treatment options for various forms of cancer, with the goal of establishing its therapies as a standard of care in oncology.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutic solutions for psychiatric and neurological disorders, with an emphasis on non-hallucinogenic and rapid-acting agents. Psylo's mission is to develop improved medications that can serve as effective alternatives to traditional selective serotonin reuptake inhibitors (SSRIs), thereby enhancing treatment options for mood disorders, addiction, and certain neurological diseases. By leveraging psychedelic molecules as the foundation for its innovative therapies, Psylo seeks to make significant advancements in mental health treatment.

Operator of a cancer immunotherapy company intended to develop medicines to treat primary, recurrent and metastatic cancers. The company uses several different technologies and approaches utilizing viral vectors and affinity agents that can be conjugated to deliver biologicals, enabling doctors to utilize new and advanced treatments to cure patients even in advanced stages of cancer.

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Tin Alley Ventures is a venture capital investment firm based in Melbourne, Australia, founded in 2022. The firm focuses on investing in technology startups at various stages, including seed, early, and later stages. It collaborates closely with companies and researchers within the University of Melbourne's ecosystem, aiming to support and develop businesses that have the potential to create significant social and economic impact. Through its strategic partnerships and investment approach, Tin Alley Ventures seeks to foster innovation and drive growth in the technology sector.

Carina Biotech is a biotechnology company focused on developing innovative cellular immunotherapies to treat various cancers, with an emphasis on childhood and rare cancers. The company specializes in chimeric antigen receptor T cell (CAR-T) therapies, which involve engineering the patient's own immune system to target and eliminate cancer cells. Carina Biotech is dedicated to improving therapeutic access to solid tumors and enhancing the manufacturing processes of CAR-T cells, thereby broadening the applicability of its treatments across a range of solid cancers. Through its cutting-edge research and development, Carina Biotech aims to provide more effective options for patients affected by challenging malignancies.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Emyria Limited is a healthcare technology and services company based in West Leederville, Australia. Founded in 2018, it operates a network of specialist medical clinics that provide patient-focused treatments, including cannabinoid-based medicines. Emyria is committed to advancing treatment development and enhancing patient care through data-driven approaches. The company has also established a partnership with Mind Medicine Australia to co-develop a clinical model for the safe provision of psychedelic-assisted therapies in Australia. Emyria, previously known as Emerald Clinics Limited, reflects a dedication to innovative healthcare solutions and evidence-based practices.

Mindset Health is a digital therapeutics company based in Melbourne, Victoria, founded by Alex Naoumidis in 2018. The company develops an app-based hypnotherapy platform designed to help individuals manage chronic health issues, particularly irritable bowel syndrome, anxiety, and chronic pain. The platform offers a safe and nonaddictive alternative for treatment, allowing users to improve their conditions without the need for dietary changes. In addition to addressing irritable bowel syndrome, Mindset Health's solutions aim to enhance sleep quality and reduce stress, anxiety, and pain associated with various chronic conditions. Through its innovative approach, Mindset Health provides accessible and cost-effective healthcare options for those seeking relief from chronic health challenges.

SpeeDx is a company that specializes in molecular diagnostic solutions, offering advanced testing systems that provide comprehensive information for enhanced patient management. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx develops market-leading multiplex detection and priming strategies. Its product portfolio includes diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By focusing on multiplex systems, SpeeDx enables healthcare providers to efficiently test for various infectious diseases and assess antibiotic resistance, thereby improving clinical decision-making and patient outcomes.

CurveBeam AI develops, manufactures, operates, and sells artificial intelligence tools for bone analysis.

Inventia Life Science Pty Ltd is an Australian company founded in 2013 and based in Alexandria. It specializes in 3D bioprinting technology aimed at enhancing cell-based research and clinical applications. The company develops, manufactures, and sells equipment, reagents, and bio-inks—both natural and synthetic—designed for advanced medical research. Inventia's innovative approach focuses on creating low-cost and standardized methods for producing three-dimensional human tissue and organ models. This technology is intended to accelerate cancer research, drug discovery, and advancements in regenerative medicine. By providing a comprehensive suite of hardware, software, consumables, and customized protocols, Inventia Life Science facilitates the flexible production of 3D cell-based assays, significantly impacting the medical research landscape.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergy. Founded in May 2015, the company emerged from the acquisition of intellectual property developed by Alfred Health and Monash University. Aravax's innovative approach involves proprietary technology that aims to reset the immune system, allowing patients to tolerate peanuts without experiencing allergic reactions during treatment. The company's focus is on creating vaccines that mitigate the risk of life-threatening responses to peanuts, providing a potential solution for individuals suffering from peanut allergies.

Perx Health is a digital care management program focused on enhancing treatment adherence among high-risk members with chronic conditions. Tailored specifically for clinically complex patients, the platform effectively manages various health issues, including diabetes and behavioral health, by employing a range of motivational techniques that address low health literacy. Perx Health's approach integrates reminders, education, and monitoring of medication regimens, while also utilizing gamification and rewards to encourage consistent medication adherence. This innovative strategy has resulted in a remarkable 90% adherence rate, leading to significant clinical improvements in metrics such as HbA1C and cholesterol control. Health plans utilizing Perx Health's services experience substantial cost savings and a high return on investment, underscoring the program's effectiveness in driving patient engagement and improving health outcomes.